Sutro Biopharma, Inc.
As of Oct 22, 2026, Sutro Biopharma is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $10.29, 74.8% below its 52-week high and below its 200-day average, which is rising.
Sutro Biopharma, Inc. operates as an oncology company. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is STRO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
STRO among Biotechnology225th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …225 | STRO | Stage 4 · wk 6 | 44 | −34.6% |
Sutro Biopharma: quick answers
What stage is Sutro Biopharma in?
As of Oct 22, 2026, Sutro Biopharma (STRO) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean
Is Sutro Biopharma in an uptrend?
No. Sutro Biopharma is in a Stage 4 downtrend. It trades 55.5% below its 200-day average, which is rising.
How far is Sutro Biopharma from its 52-week high?
Sutro Biopharma closed at $10.29 on Oct 22, 2026, 74.8% below its 52-week high of $40.91. Its 52-week low is $7.30.
How has Sutro Biopharma performed over the past year?
As of Oct 22, 2026, Sutro Biopharma is down 14.3% over the past year and down 6.1% so far in 2026.
Which sector and industry is Sutro Biopharma in?
Sutro Biopharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.